Shield Therapeutics plc (STX) Ordinary Shares 1.5p

What is happening?

Shield Therapeutics (STX) have announced their intention to raise up to £8.7 million via a Subscription (for Institutional Investors) and a Retail Offer (for Individual Investors).

Shield Therapeutics (STX) have decided not to issue a Prospectus as part of the fundraising. This means that the Retail Offer has been limited to the Sterling equivalent of €8 million and may only be open for a number of hours. It also means that information relating to the fundraising is limited to the Company announcement.

• Applications are due to close at 3:30pm on Friday 20 December. Due to the nature of the fundraising, applications can close at any time and without prior warning.

• Shares are being offered at a fixed price of 3 pence.

• The minimum application for the Retail Offer is £50.

• By applying for shares in the Retail Offer you are deemed to have read, understood and agreed to the HL Retail Offer Risk Warnings, Terms and Conditions and the Company Announcement.

• Hargreaves Lansdown will receive 0.5% commission from the Issuer as part of the Offer.

• The Retail Offer is capped at a maximum of £1 million, meaning that if the total value of applications received by the Issuer exceeds this figure, a scaling back policy is likely to be applied.

What are my options?

Option 1 – Do Nothing. If you do not return an election by the deadline of 3:30pm on Friday 20 December, the Offer will lapse.

Option 2 – You can choose to buy new Shares at 3 pence. If you wish to submit an order outside of the product you currently hold your shares, please leave a note in the comments section of the application.

When do I have to decide by?

Any instruction to participate in the Retail Offer must be received by 3:30pm on Friday 20 December. If no instruction is received the Offer will lapse.

Before submitting an instruction, you should carefully read the Company Announcement, HL Retail Offer Risk Warnings & Terms and Conditions which are attached to the Retail Offer notification. You can find this in the Secure Messaging Centre of your online account. By submitting an instruction, you are deemed to have read and understood these documents as well as agreed to any terms within.

What happens after I apply?

If you apply for shares you will receive two Secure Messages. The first will confirm your application and be sent shortly after 4:30pm on Friday 20 December. The second will confirm how many shares you have been allocated and be sent once the results have been announced on Monday 23 December.

You can view your application in the Pending Orders tab of your online account from Monday 23 December.

Your new shares will be credited on Monday 30 December This may be delayed in the event the company does not deliver your shares to us by this time. Please note admission is subject to the approval of a resolution at the General Meeting expected to be convened on Tuesday 24 December.

To assist the Company during the allocation process, we may be required to disclose the number of Shield Therapeutics (STX) shares you hold with Hargreaves Lansdown. We will do this by calculating the shares held in your Hargreaves Lansdown account at the close of business on Thursday 19 December.

It should be noted that a subscription for the Retail Shares and any investment in the Company carry a number of risks. Investors should make their own investigations into the merits of an investment in the Company. This message is not personal advice and is a summary of the Shield Therapeutics (STX) announcement.

If you require any assistance, please contact our Helpdesk on 0117 900 9000.